Changes

Jump to: navigation, search

Oral Diabetes Drugs

1,509 bytes added, 06:48, 6 August 2009
/* Prevalence */
|}
===<span style="color:#C41E3A">Like this report?</span>===
<p align="center"> '''This is only a sample report with brief analysis''' <br>
'''Dolcera can provide a comprehensive report customized to your needs'''</p>
{|border="2" cellspacing="0" cellpadding="4" align="center" "
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]'''
|-
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
|-
|}
<br>
===Prevalence===
The prevalence of diabetes( Both type I and type II ) in U.S. during the years 1980 to 2005, increased from 5.6 million to 15.8 million (Figure 4). Especially people aged from 65 to 74 had the highest prevalence compared to other age groups (Figure 5). The prevalence of the disease was similar in both men and women till the year 1998 but from 1999, the prevalence of the disease increased highly in men compared to females (Figure 6).